{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:47:37Z","timestamp":1761842857827},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,1,13]],"date-time":"2002-01-13T00:00:00Z","timestamp":1010880000000},"content-version":"vor","delay-in-days":165,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutic Apheresis"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>Familial hypercholesterolemia (FH) is a congenital disorder of cholesterol metabolism, which is due to a deficiency in low\u2010density lipoprotein (LDL) receptors. The homozygous form of FH is especially liable to coronary artery disease (CAD) in youth because of the very high LDL\u2010cholesterol levels. It is resistant to drug therapy, and LDL\u2010apheresis is the only practical way of treatment for these patients. Some patients with heterozygous FH also have high LDL\u2010cholesterol levels that cannot be brought down into the optimum range by any combination drug therapy. We have treated or are treating 10 homozygous and 28 heterozygous FH patients in our hospital or in affiliated hospitals expert in blood purification. Among the 10 homozygous patients, 2 died of myocardial infarction. Only one young female patient is still free of symptoms, and the other patients have been suffering from regurgitation through the aortic valve although they have not experienced myocardial infarction. Rapid rebound of LDL\u2010cholesterol after each apheresis treatment limits the period during which LDL\u2010cholesterol is in the optimum range. The use of atorvastatin at a high dose (40 mg\/day) was attempted to suppress this rebound. In contrast with good results in receptor\u2010defective\u2010type patients, receptor\u2010negative\u2010type patients did not show a response in LDL\u2010cholesterol levels to the statin therapy although there was a slight increase in high\u2010density lipoprotein (HDL)\u2010cholesterol with a decrease in very\u2010low\u2010density lipoprotein\u2010triglyceride and \u2010cholesterol. Follow\u2010up study of the patients with heterozygous FH revealed that LDL\u2010apheresis was effective in lengthening the life expectancy of the patients with pre\u2010existing CAD, especially those who had received intervention coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA). It was also shown that the use of probucol in combination with LDL\u2010apheresis was effective in reducing coronary events as shown by the necessity of CABG or PTCA. Clinical data on the effect of LDL\u2010apheresis, recently reported from some other institutions in Japan, will also be reviewed.<\/jats:p>","DOI":"10.1046\/j.1526-0968.2001.00328.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:00:37Z","timestamp":1047502837000},"page":"221-225","source":"Crossref","is-referenced-by-count":23,"title":["Apheresis Technology for Prevention and Regression of Atherosclerosis"],"prefix":"10.1111","volume":"5","author":[{"given":"Akira","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Harada\u2010Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akito","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,13]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"1377","article-title":"Forme homozygotes cutaneo\u2010tendineuses des xanthomatose hypercholesterolemique dans une observation familielle exemplaire. Essai de plasmapherese a titre de traitment heroique.","volume":"118","author":"DeGennes JL","year":"1967","journal-title":"Bull Mem Soc Hop Paris"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6510.1671"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.43.6.680"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.51.1116"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1997.tb00144.x"},{"key":"e_1_2_8_7_2","first-page":"1261","article-title":"A new approach to the management of familial hypercholesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography.","volume":"1","author":"Lupien P\u2010J","year":"1975","journal-title":"Lancet"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.4.3.276"},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2362.1989.tb00192.x","article-title":"Improved haemorrheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin\u2010induced extracorporeal LDL precipitation.","volume":"19","author":"Schuff\u2010Werner P","year":"1989","journal-title":"Eur J Clin Invest"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2000.06476.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920040204"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.1995.tb02369.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.76"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(92)90170-L"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(98)00328-1"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1997.tb00149.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01727783"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(98)00692-4"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92961-4"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.10.1826"},{"key":"e_1_2_8_21_2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0022-2275(20)37137-6","article-title":"Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.","volume":"38","author":"Marais AD","year":"1997","journal-title":"J Lipid Res"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(00)00373-7"}],"container-title":["Therapeutic Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-0968.2001.00328.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-0968.2001.00328.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T17:07:01Z","timestamp":1704301621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-0968.2001.00328.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1046\/j.1526-0968.2001.00328.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-0968.2001.00328.x","archive":["Portico"],"relation":{},"ISSN":["1091-6660","1526-0968"],"issn-type":[{"value":"1091-6660","type":"print"},{"value":"1526-0968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}